Lastly, miR-507, miR-634, miR-450a and miR-129-5p were shown to negatively modulate to NRF2 oncogenic activity by directly targeting NFE2L2 in the neuroblastoma SH-SY5Y cell line [123], whereas it was demonstrated that they could exert a synergic effect of increasing sensitivity to cisplatin treatment in NSCLC A549 cells [124]. This evidence concerns the gene NFE2L2 and neuroblastoma.